Skip to main
THC

Tenet Healthcare (THC) Stock Forecast & Price Target

Tenet Healthcare (THC) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 56%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Tenet Healthcare's positive outlook is bolstered by its continued investment in the USPI segment, which is characterized by faster growth, higher margins, and improved returns. The company anticipates a steady increase in return on invested capital (ROIC), underpinned by strong demand, a favorable payer mix, and effective cost management initiatives, contributing to enhanced visibility into margin expansion. The ongoing transformation within Tenet's operations, especially through the USPI segment, positions it for significant financial advancements in the coming years.

Bears say

Tenet Healthcare's stock faces a negative outlook due to substantial potential headwinds from subsidy expirations, estimated at $220 million for its Acute segment and $30 million for its United Surgical Partners International (USPI) segment, which are projected to impact the 2026 financial forecast significantly. Additionally, the anticipated 20% decline in Health Insurance Exchange (HIX) coverage may lead to 80-85% of affected individuals becoming uninsured, resulting in decreased utilization of healthcare services. While Tenet recorded a temporary boost from $148 million in non-recurring Medicaid state funds in 2025, this is seen as insufficient to counterbalance the looming structural challenges and financial pressures the company faces.

Tenet Healthcare (THC) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 56% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenet Healthcare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenet Healthcare (THC) Forecast

Analysts have given Tenet Healthcare (THC) a Buy based on their latest research and market trends.

According to 18 analysts, Tenet Healthcare (THC) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $243.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $243.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenet Healthcare (THC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.